Search results
University College London School of Pharmacy - Cited by 2,440 - Pharmaceutics - Pulmonary Drug Delivery
Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure.
- Michael Y.T. Chow, Michael Y.T. Chow, Yingshan Qiu, Jenny K.W. Lam
- 2020
They eventually formed a relationship with strategic partner Michael Y. Chow, co-founder of XRM Media, a media technology company targeting Generation Z and millennial audiences, and managing partner of MNM Creative, a multi-media and entertainment company with offices in Shanghai and China.
Michael Y.T. Chow's 33 research works with 1,650 citations and 21,161 reads, including: Delivery technology of inhaled therapy for asthma and COPD
This chapter provides an overview of inhaled therapy for the management of asthma and COPD. The operation principles, merits and limitations of different delivery technologies are examined. Looking ahead, the challenges of delivering novel therapeutics such as biologics through the pulmonary route are also discussed.
Pulmonary delivery of therapeutic biologics enables the potential for safe and effective treatment option for respiratory diseases due to high bioavailability while minimizing absorption into the systemic circulation, reducing off-target toxicity to other organs.
View Michael Y. Chow’s profile on LinkedIn, a professional community of 1 billion members. Experience: XRM Media · Education: The University of Texas at Austin · Location: Los Angeles · 500...
- XRM Media
